Biomark Capital Management Co. LLC - Q3 2017 holdings

$88.1 Million is the total value of Biomark Capital Management Co. LLC's 3 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was - .

 Value Shares↓ Weighting
No holdings reported for quarter Q3 2017
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Biomark Capital Fund IV GP LLC #1
  • David S. Wetherell #2
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2017-10-30
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ADMA BIOLOGICS, INC.12Q3 2018100.0%
JUNO THERAPEUTICS, INC.9Q4 201795.0%
MABVAX THERAPEUTICS HOLDINGS, INC.6Q4 20170.2%
MABVAX THERAPEUTICS HOLDINGS, INC.3Q2 20160.2%
MABVAX THERAPEUTICS HOLDINGS, INC.3Q3 20180.2%

View Biomark Capital Management Co. LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2018-10-24
13F-HR2018-08-09
13F-HR2018-04-20
13F-HR2018-02-13
13F-HR2017-10-30
13F-HR2017-08-08
13F-HR2017-05-11
13F-HR2017-02-13
13F-HR2016-11-09
13F-HR2016-08-12

View Biomark Capital Management Co. LLC's complete filings history.

Compare quarters

Export Biomark Capital Management Co. LLC's holdings